Cargando…
A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma
AIM: We have previously reported that polyfunctional T cell responses can be induced to the cancer testis antigen NY-ESO-1 in melanoma patients injected with mature autologous monocyte-derived dendritic cells (DCs) loaded with long NY-ESO-1-derived peptides together with α-galactosylceramide (α-GalC...
Autores principales: | Dasyam, Nathaniel, Sharples, Katrina J., Barrow, Catherine, Huang, Ying, Bauer, Evelyn, Mester, Brigitta, Wood, Catherine E., Authier-Hall, Astrid, Dzhelali, Marina, Ostapowicz, Tess, Kumar, Rajiv, Lowe, Jessica, Maxwell, Alice, Burn, Olivia K., Williams, Geoffrey M., Carley, Sarah E., Caygill, Graham, Jones, Jeremy, Chan, Susanna T. S., Hinder, Victoria A., Macapagal, Jerome, McCusker, Monica, Weinkove, Robert, Brimble, Margaret A., Painter, Gavin F., Findlay, Michael P., Dunbar, P. Rod, Gasser, Olivier, Hermans, Ian F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264280/ https://www.ncbi.nlm.nih.gov/pubmed/36881133 http://dx.doi.org/10.1007/s00262-023-03400-y |
Ejemplares similares
-
Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)
por: George, Philip, et al.
Publicado: (2020) -
Co-Delivery of the Human NY-ESO-1 Tumor-Associated Antigen and Alpha-GalactosylCeramide by Filamentous Bacteriophages Strongly Enhances the Expansion of Tumor-Specific CD8+ T Cells
por: Manco, Roberta, et al.
Publicado: (2023) -
NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
por: Thomas, Remy, et al.
Publicado: (2018) -
Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells
por: Gong, Wenjie, et al.
Publicado: (2021) -
Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients
por: Kageyama, Shinichi, et al.
Publicado: (2013)